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Abstract 
Objectives: To investigate the impact of dystonia symptoms upon cognitive 
functioning, by comparing cognitive performance in focal and generalised dystonia 
subtypes, and examining the differential contribution of severity of symptoms and 
mood disorder.  
Background: Studies investigating the non-motor syndrome in isolated dystonia have 
reported evidence of cognitive dysfunction. However, the cause of this cognitive 
impairment remains unclear. Several studies have suggested that poor cognitive 
performance reflects the distracting effects of the motor symptoms and/or mood 
disorder.  
Methods: 25 cervical dystonia patients were compared with 13 generalised dystonia 
patients and 50 healthy controls on an extensive battery of cognitive and mood 
assessments.  
Results: Cognitive performance was found to be independent of all clinical and mood 
variables. We found no significant differences in cognitive performance between the 
two dystonia groups. The whole dystonia group demonstrated significant impairment 
on only one measure of cognitive functioning, namely the Trail Making test. Two 
patients also showed impairment on one further measure, the Stroop test, and dystonia 
patients demonstrated more frequent impairment on the Hayling Sentence Completion 
Test. 
Conclusions: This study suggests the presence of a subtle executive deficit in dystonia, 
not accounted for by dystonia subtype, severity of symptoms or medication burden. 
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Introduction 
Isolated dystonia, formerly referred to as primary dystonia, is a movement disorder, 
characterised by sustained muscle contractions, leading to twisting and repetitive 
movements, and/or abnormal postures which occur in the absence of any structural or 
chemical abnormality (see Fahn, Marsden & Calne, 1987). Distribution of ensuing 
motor symptoms may be focal, affecting one region only; segmental or multi-focal, 
affecting at least two regions; or generalised, affecting the trunk and at least two other 
regions (Albanese et al., 2013). Underlying aetiology may be inherited, acquired or 
idiopathic (Albanese et al., 2013); with at least three causative genes identified and 
validated (including DYT1, DYT6, DYT25; Dauer et al., 2014)  
 
In addition to these often disabling motor symptoms, several studies have reported 
abnormalities in cognition (Stamelou et al., 2012). However, there has been some 
inconsistency in the abnormalities reported, with several conflicting findings, and some 
studies reporting no impairment at all (Ostrem et al., 2011; Taylor et al., 1991; van 
Tricht et al., 2012). Thus, the evidence for cognitive impairment in dystonia remains 
controversial. 
 
This may reflect the methods used to assess the cognitive profile. Some studies have 
suggested preserved cognition in dystonia on the basis of a brief assessment battery 
only (Taylor et al., 1991). A more comprehensive study by Scott et al. (2003) found 
intact performance on a range of standard measures of cognitive and executive 
functioning, but also selective impairment on one test of executive functioning from 
the CANTAB (Intra/Extra Dimensional Set-Shifting Task). Other investigations have 
also revealed scattered impairments, mostly on tests of executive functions. For 
example, Jahanashahi, Rowe and Fuller (2003) reported impairments in category 
fluency and dual tasking; Bugalho and colleagues (2008) reported an increased number 
of perseverations on the Wisconsin Card Sorting Test; and van Tricht et al. (2012) 
reported impairment in category fluency and the Trail Making Test – part B. A few 
studies have also reported impairment in visual and verbal memory (Balas et al., 2006; 
Romano et al., 2012).  
 
It has been argued that any cognitive deficits observed may simply reflect other more 
basic factors, such as the distracting effects of motor symptoms (Stamelou et al., 2012). 
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In keeping with this, Allam and colleagues (2007) found that cognitive performance in 
nine patients with cranial dystonia improved following treatment with botulinum toxin.  
Yet, a larger, subsequent study found cognitive functioning in 20 patients with 
blepharospasm was independent of symptom severity or duration (Gonzalez Alemán, 
de Erausquin & Micheli, 2009). Thus, it remains unclear if the motor symptoms can 
fully account for the cognitive deficits noted.  
 
It is noted that no study to date has directly compared cognition across different 
dystonia subtypes. Should the cognitive deficits simply reflect the intrusiveness of 
motor symptoms, it may be hypothesised that more generalised and/or severe symptoms 
would be associated with greater cognitive impairment than that observed in patients 
with more focal or milder presentations. 
 
Furthermore, although it is well recognised that the incidence of mood disorder is 
elevated in dystonia (Bugalho et al., 2008; Kleiner-Fisman et al., 2007; Ostrem et al., 
2011; van Tricht et al., 2012), few studies have examined the relationship between 
cognitive performance and mood. Van Tricht et al. (2012) found that patients with 
isolated dystonia who also had a history of anxiety performed worse on a measure of 
working memory, and Jahanashahi et al. (2003) found that those with higher depression 
scores performed worse on a measure of executive functioning. This raises the 
possibility that any cognitive impairment may reflect the impact of mood disorder.  
 
The aims of the present study were to: (1) compare cognition between dystonia patients 
and age-matched healthy controls; (2) determine if there are any differences in 
cognitive performance between generalised and cervical dystonia; (3) consider the 
impact of other relevant clinical factors, such as severity of symptoms and medication 
burden and (4) examine the relative contribution of mood. 
 
 
Methods 
Participants 
Patients with a diagnosis of cervical or generalised dystonia who attended the 
Neuropsychology Department of the National Hospital for Neurology and 
Neurosurgery, Queen Square, London, were screened for eligibility. These patients had 
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been referred as part of a multi-disciplinary assessment for determining suitability for 
surgical treatments for dystonic symptoms. Exclusion criteria were: i) previous history 
of traumatic, neurological, psychiatric or systemic disorder; ii) history of alcohol/drug 
abuse; and iii) non-native English speaker. Application of these exclusion criteria 
resulted in five patients being excluded (n = 2, dystonia secondary to post-anoxic injury; 
n = 1, tardive dystonia; n = 1, history of alcoholism; n = 1, non-native English speaker). 
The remaining patients consisted of 25 cervical and 13 generalised dystonia. Over half 
of the generalised dystonia patients (69.2%, n = 9) had likely inherited forms (n = 7, 
DYT1; n = 1, DYT6; n = 1, autosomal dominant pattern of inheritance, but with no 
specific gene identified), with the four remaining generalised dystonia patients having 
a diagnosis of idiopathic isolated dystonia (negative for DYT1).  
 
A total of 50 age-matched healthy controls were also recruited. These had no known 
history of traumatic, neurological, psychiatric or systemic disorder, no history of 
alcohol/drug abuse, and were native English speakers. The characteristics of the three 
participant groups are shown in Table 1. 
 
 
-- Table 1 around here-- 
 
 
Severity of dystonia was independently rated by a Neurologist using the Burke-Fahn-
Marsden Dystonia Rating Scale in the patient’s optimal condition. A total of 33 (86.8 
%) of the dystonia patients were taking medication at the time of testing (84.0 % of the 
cervical and 92.3 % of the generalised dystonia patients). These medications included 
anti-muscarinics (trihexyphenidyl [n = 11, 28.9 %], botulinum toxin [n = 18, 47.4 %], 
and tetrabenazine [n = 1, 2.6 %]); hypnotics (clonazepam [n = 7, 18.4 %], diazepam [n 
= 6, 15.8%], and chlorodiazepoxide [n = 1, 2.6 %]), relaxants (baclofen [n = 2, 5.3%]), 
and antidepressants (n = 7, 18.4%). 
 
The research was done in accordance with the Helsinki declaration and the Institute of 
Neurology Joint Research Ethics Committee UCLH, NHS Trust Research and 
Development Directorate. 
Cognitive assessment 
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All of the patient participants completed the following standardised neuropsychological 
assessments, assessing general intellectual functioning, memory abilities, attentional 
and executive functioning, speed of processing, and mood: 
 
1. Global cognitive functioning 
Current level of intellectual functioning was assessed using the Wechsler Adult 
Intelligence Scale – Third Edition (WAIS-III; Wechsler et al., 1997), pro-rated to 
generate scores for verbal (VIQ) and non-verbal intellectual abilities (PIQ). The 
National Adult Reading Test (NART; Nelson, 1982) was used in order to estimate 
premorbid level of intellectual functioning, by generating each patient’s Predicted Full-
Scale IQ (PFSIQ). The MMSE was administered as a screening test of global cognitive 
functioning (Folstein, Folstein & McHugh, 1975). Additional tests of naming (Graded 
Naming Test; McKenna & Warrington, 1983) and visuoperceptual skills (Silhouettes 
and/or Incomplete Letters from the Visual Object and Space Perception Battery; 
Warrington & James, 1991) were also administered to confirm the absence of a global 
cognitive disorder.  
 
2. Memory 
Visual and verbal recognition memory were assessed using the Recognition Memory 
Tests (RMT; Warrington, 1984). 
 
3. Attentional and executive functioning 
Attentional and executive functioning was assessed using the Elevator Counting 
subtests from the Test of Everyday Attention (TEA; Robertson et al., 1994), part B of 
the Trail Making Test (TMT-B; Reitan & Wolfson, 1985), Modified Card Sorting Test 
(MCST; Nelson, 1976), Brixton Spatial Anticipation Test (Burgess & Shallice, 1997), 
Stroop (Trenerry et al., 1989), Hayling Sentence Completion Test (Burgess & Shallice, 
1997) and phonemic verbal fluency (FAS; Spreen & Strauss, 1998). 
 
4. Speed of processing 
Speed of information processing was assessed using part A of the Trail-Making Test 
(TMT-A; Reitan & Wolfson, 1985) and the Symbol Search and Digit Symbol Coding 
subtests from the WAIS-III (Wechsler, 1997).  
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5. Mood 
All patients were screened for mood disorder using the Hospital Anxiety and 
Depression Scale (HADS; Zigmond & Snaith, 1983) and the Apathy Evaluation Scale 
(AES; Marin, Biedrzycki & Fririniciogullari, 1991). 
 
The healthy controls completed an abbreviated version of this full assessment, 
comprising the WAIS-III, NART, RMT, TMT-B, Stroop, Hayling Sentence 
Completion Test and TMT-A. 
 
Statistical analysis 
Means and standard deviations were calculated for each of the raw scores on the 
measures. Before analysis, all data underwent log transformation to achieve near-
normal distributions. Frequency of impairment (scores of less than 5th percentile) on 
each test was also calculated relative to published normative data. 
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Results 
 
Patient participants 
All patients scored at or above 27/30 on the MMSE and above the 5th percentile on the 
Graded Naming Test and the Silhouettes and/or Incomplete Letters tests of visual 
functioning.  
 
Cervical vs generalised dystonia 
As shown in Table 1, the generalised dystonia patients were significantly younger than 
the cervical dystonia patients [t (36) = -5.04, p < .001, r = .45], but there were no 
significant differences in NART PFSIQ. The generalised dystonia group also had a 
significantly younger age of disease onset than the cervical group [t (34) = -5.25, p < 
.001, r = .67], as well as greater severity of movement disorder [t (14) = 4.35, p < .001, 
r = .76] and disability [t (14) = 4.30, p < .001, r = .75].  
 
Neuropsychological performance was compared between the two dystonia groups 
(Table 2). Mean test scores were compared using analyses of covariance (ANCOVA), 
with age as a covariate, and adjusted using Bonferroni correction.  
 
--Table 2 around here-- 
 
As shown in Table 2, there were no significant differences in neuropsychological 
performance between the two dystonia groups. Further, chi-square tests revealed no 
significant associations between the type of dystonia and frequency of impairment on 
the neuropsychological assessments. 
 
Dystonia vs healthy controls 
The dystonia group was compared with healthy controls. There were no significant 
differences in mean age, NART, WAIS-III or memory. However, the dystonia group 
performed significantly worse on the TMT-B [t (54) = 4.05, p < .001, r = .43] and TMT-
A [t (53) = 2.25, p < .05, r = .32]. TMT-A was related to performance on the TMT-B 
[F (1, 52) = 21.75, p < .001, r = .99]. However, there remained a significant difference 
in TMT-B after controlling for TMT-A [F (1, 52) = 9.62, p < .05, r = .81] between the 
dystonia group and healthy controls. Although there was no significant group difference 
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in mean age between the two dystonia patient groups, an ANCOVA was performed to 
consider if the differing age ranges may contribute to the significant group difference 
in TMT-B performance. This confirmed that age was not a significant factor. In 
addition, although a chi-square test revealed no significant association between 
participant type and frequency of impairment, it is notable that five of the dystonia 
patients (13.2 %) performed in the impaired range on TMT-B (< 10th percentile), 
whereas none of the healthy controls did, and no participant did on TMT-A.                   
 
The dystonia patients also performed significantly worse than healthy controls on the 
Stroop [t (44.71) = -2.11, p < .05, r = .27]. However, despite log transformation, the 
dystonia patients’ scores remained significantly negatively skewed [zskewness = -6.98], 
with insufficient homogeneity of variance [F (1, 70) = 10.73, p < .05]. Again, a chi-
square test revealed no significant association between participant type and frequency 
of impairment, but four of the dystonia patients (10.5 %) performed in the impaired 
range (< 10th percentile), whereas none of the healthy controls did. Two of these patients 
scored significantly below the group mean (zStroop: -4.67 and -2.68). The first of these 
patients had cervical dystonia and was taking botulinum toxin. The second had DYT1 
generalised dystonia and was on antidepressant medication. When these two outliers 
were removed from the analysis, the group difference was no longer significant.  
 
A chi-square test did reveal a significant association between participant type and 
frequency of impairment on the Hayling, with six of the dystonia patients (17.1 %) 
performing in the impaired range (< scaled score 4), whereas none of the healthy 
controls did [χ2 (1) = 5.85, p < .05]. However, an ANOVA revealed no significant 
difference in mean scores. 
 
In sum, nearly a third of all dystonia patients (n = 12, 31.6 %) performed in the impaired 
range on at least one of the TMT-B, Stroop and Hayling tests. One patient performed 
in the impaired range on all three, one patient was impaired on the Stroop and Hayling 
only, and the 10 remaining patients were impaired on only test (TMT-B: n = 4; Hayling: 
n = 4; Stroop: n = 2): Both of the patients with one than one impairment had a diagnosis 
of cervical dystonia, but the remaining patients had equally frequent diagnoses of 
cervical and generalised dystonia (both n = 5). Post-hoc analyses revealed no significant 
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group differences between those who were impaired on at least one test and those who 
were unimpaired in age, mood or severity of dystonia. 
 
Contribution of disease variables 
The role of age of disease onset, duration of illness, severity of movement disorder, or 
severity of disability was considered with the whole group. There were no significant 
correlations between neuropsychological performance and disease variables. 
Furthermore, when patients were separated into two groups according to severity of 
movement disorder, using a median split, no significant differences in 
neuropsychological performance was found.  
 
There were no significant differences in neuropsychological performance between 
those using medications (n = 33) and those not (n = 5), after Bonferroni correction, 
Furthermore, there were no significant differences in those using medications thought 
to have greater cognitive side-effects (trihexyphenidyl, hypnotics: n = 15) and those 
who were not (n = 23). 
 
Mood assessment 
The dystonia patients disclosed high rates of mood disorder on the HADS and AES. 20 
of the patients (52.6 %) scored above cut-off for anxiety, with a mean score of 7.53 (SD 
= 3.97). 11 of the patients (28.9 %) scored above cut-off for depression, with a mean 
score of 5.79 (SD = 3.75). 14 of the patients (36.8 %) scored above cut-off for apathy, 
with a mean score of 12.00 (SD = 8.02), and seven of these reached scored above cut-
off for both depression and apathy. Depression and anxiety scores were highly 
intercorrelated (r = .63, p <.001), with a significant association between depression and 
apathy (r = .59, p < .001). 
 
There were no significant differences in mood between the two dystonia groups. Mood 
was not significantly related to age of disease onset, duration of disease, severity of 
movement disorder or disability. When those endorsing high levels of mood disorder 
(scores > 11 for either anxiety or depression: n = 7) were compared with those endorsing 
only minimal levels (both scores < 8: n = 19), there were no significant group 
differences. Mood was also not associated with performance on any of the 
neuropsychological measures, and there was no significant association between level 
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of mood disorder (high/low) and frequency of impairment on neuropsychological 
assessments or severity of symptoms.  
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Discussion 
Several studies have reported cognitive impairment in dystonia and have argued that 
this may simply reflect the distracting effects of the dystonia symptoms and/or mood 
disorder. We compared cognitive performance in patients with focal and generalised 
dystonia subtypes on a comprehensive range of neuropsychological assessments. We 
found no significant differences between cervical and generalised dystonia patients in 
mean performance or frequency of impairment. This is despite the fact that generalised 
dystonia patients have more severe and disabling motor symptoms than the cervical 
patients. This suggests that severity of motor symptoms has little or no impact upon 
cognitive performance.  
 
Indeed, our correlational analyses revealed no significant associations between severity 
of symptoms and performance on any measure of cognitive functioning. Cognitive 
performance was also not associated with age of onset or duration of illness. There was 
no significant difference in cognitive performance between those using and not using 
any medication, or those using and not using medication with greater cognitive side-
effect profiles. Although subgroup numbers precluded further analysis of any more 
fine-grained medication effects, the current findings suggest that cognitive performance 
is independent of these clinical variables. 
 
When we compared dystonia patients with healthy controls, we found that the dystonia 
patients on the whole performed less well on the Trail-Making Test. Two patients also 
showed impairment on a further measure, the Stroop test. In addition, patients 
demonstrated significantly more frequent impairment on the Hayling Sentence 
Completion Test. In total, nearly a third of all dystonia patients demonstrated 
impairment on at least one test of executive functioning in comparison with none of the 
healthy controls. This relative deficit in executive functioning is in keeping with several 
previous reports (van Tricht, Scott et al., 2003; Jahanashahi et al., 2003; Bugalho et al., 
2008; Romano et al., 2012; Kleiner-Fisman et al., 2007). Importantly, this deficit does 
not appear to be explained by a more basic fluctuation in attentional abilities caused by 
distracting effects of dystonic symptom, as severity of symptoms was not related to 
performance on any measure of executive functioning. 
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However, it should be stated that poor performance on the Trail-Making Test has been 
found to be an unspecific marker of brain dysfunction (Chan et al., 2015; Demakis, 
2004). It also remains unclear whether any strong conclusions can be drawn on the basis 
of impaired Stroop performance in two patients only. Thus, although this study found 
evidence of subtle cognitive symptoms, which may have significant implications for 
the patients and should be recognised as part of the syndrome, there was no indication 
of a pervasive or significant cognitive impairment. The subtlety of these cognitive 
symptoms may explain why several previous studies have reported preservation of 
cognitive functioning in dystonia (Ostrem et al., 2011; Taylor et al., 1991; Vidalihet et 
al., 2005). 
 
It seems unlikely that the little evidence of cognitive impairment found in this patient 
sample is simply attributable to the number of participants. Our patient sample of 38 is 
larger than most previously published studies (Ostrem et al., 2011; Taylor et al., 1991; 
Scott et al., 2003; Jahanashahi et al., 2003; Balas et al., 2006; Kleiner-Fisman et al., 
2007; Vidalihet et al., 2005). Studies with similar size limitations and those with larger 
samples (up to n = 51) have also reported scattered impairments on tests of executive 
functioning (van Tricht et al., 2012; Bugalho et al., 2008; Romano et al., 2012). 
However, these studies have not included a healthy control sample or used a 
comprehensive battery of cognitive assessments. Thus, the significance of their findings 
remains unclear.  
 
Our investigation of the prevalence of mood disorder revealed that our patients 
demonstrated a high rate of anxiety and depression, with around half of all patients 
meeting criteria for mood disorder. These figures are very similar to those reported 
previously (van Tricht et al., 2012; Ostrem et al., 2011; Scott et al., 2003; Jahanashahi 
et al., 2003; Bugalho et al., 2008; Kleiner-Fisman et al., 2007; Kuyper et al., 2011). 
However, we found no significant relationship between mood and cognitive 
performance. Previously, a few studies have reported a correlation between mood 
symptoms and cognitive functioning (van Tricht et al., 2012; Jahanashahi et al., 2003). 
However, another large study did not (Bugalho et al., 2008) suggesting that the 
cognitive profile does not simply reflect mood. 
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Furthermore, mood symptoms were not associated with disease factors. This is in 
keeping with previous research, which has shown that the mood symptoms often 
precede onset of motor symptoms, perhaps explaining why dystonia was once thought 
of as a manifestation of a psychiatric disturbance (Kuyper et al., 2011). This raises the 
possibility that the mood disorder seen in dystonia may actually represent yet another 
clinical manifestation of the disease, rather than simply a reaction to its negative 
consequences (Fabbrini et al., 2012). Indeed, genetic analyses have also found higher 
rates of mood disorder in symptomatic and asymptomatic carriers of the DYT1 gene 
mutation when compared with healthy controls, with asymptomatic carriers 
demonstrating a four-fold increase in risk of developing depression (Heiman et al., 
2004). Thus, there is growing evidence that the mood symptoms represent an important 
facet of the dystonia non-motor syndrome.  
 
In sum, this study has shown that the poor performance on cognitive tests in dystonia 
is not simply a reflection of the distracting influence of motor symptoms and/or mood 
disorder. Rather, the non-motor syndrome of dystonia includes subtle cognitive 
symptoms and high rates of mood disorder. Both of which occur independently of 
disease severity or level of disability. Thus, it is argued that isolated dystonia is a 
tripartite disease, with motor, affective and subtle cognitive features. 
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Tables 
Table 1: Characteristics of two isolated dystonia groups and healthy controls. 
 
 Cervical 
dystonia 
Generalised 
dystonia  
Healthy 
controls  
Gender    
Male 6 6 29 
Female 19 7 21 
Age (mean years ± SD) 57.84 ± 9.73 39.15 ±12.79 50.30 ± 12.49 
Range  36 – 74  16 - 64 25 - 70 
NART Predicted Full-Scale 
IQ (mean ± SD) 
108.96 ± 12.20 103.85 ± 9.30 109.94 ± 7.96 
Range 81 – 128  91 – 118  85 - 118 
Age at disease onset (mean 
years ± SD) 
42.33 ± 14.06 18.75 ± 9.25 - 
Range  3 – 61  7 – 38  - 
Duration of illness (mean ± 
SD) 
14.75 ± 10.07 20.42 ± 8.67 - 
Range  1 – 39  4 – 33  - 
Burke-Fahn-Marsden 
Dystonia Rating Scale 
   
Movement  16.40 ± 9.66 38.42 ± 10.08 - 
Range  2 – 36 25 – 50  - 
Disability  3.00 ± 2.11 7.50 ± 1.87 - 
Range 0 – 7  4 – 9  - 
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Table 2: Mean and standard deviations of the generalised and cervical dystonia patients 
on each of the measures. 
 
  Generalised 
(Mean ± SD) 
Cervical 
(Mean ± SD) 
Healthy Controls  
(Mean ± SD) 
Intellectual 
Functioning 
WAIS-III    
VIQ 97.85 ± 12.14 103.80 ± 14.34 106.08 ± 14.15 
PIQ 99.08 ± 19.22 107.16 ± 16.86 109.38  ± 15.66 
Memory RMT    
Words 48.08 ± 2.75 45.65 ± 3.38 47.60 ± 4.87 
Faces 44.42 ± 4.52 41.09 ± 4.87 41.11 ± 4.87 
Attentional TEA    
Elevator Counting 6.55± 0.69 6.92 ± 0.28  
Elevator Counting 
with Distraction 
6.64 ± 3.08 8.25 ± 2.66  
Executive TMT-B (seconds) 89.92 ± 39.08 96.52 ± 42.30 59.53 ± 23.52 
MCST    
Categories 
achieved 
5.64 ± 1.21 5.57 ± 1.08  
Errors 2.18 ± 2.79 5.10 ± 5.54  
Brixton    
Overall scaled 
score 
6.83 ± 1.47 5.73 ± 1.61  
Errors 13.14 ± 5.76 17.22 ± 4.89  
Stroop 102.54 ± 16.12 96.92 ± 19.32 105.53 ±7.57 
Hayling  5.92 ± 1.08 5.26 ± 1.91 6.16 ± 1.07 
FAS 40.31± 9.88 44.80 ± 15.64  
Speed TMT-A (seconds) 37.33 ± 16.18 35.38 ± 11.43 28.37 ± 8.11 
Symbol Search  35.50 ± 19.44 26.76 ± 7.02  
Digit Symbol 55.25 ± 18.63 57.12 ± 14.65  
  
 
